A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2021; you can also visit the original URL.
The file type is
Quantifying the Costs of Care Among Patients With High-Risk Non-Muscle-Invasive Bladder Cancer Treated in the Veterans Health Administration
JAMA Network Open
Bladder cancer is one of the most expensive malignant neoplasms to manage on a per-patient basis. 1 Approximately 70% of patients with newly diagnosed bladder cancer present with non-muscleinvasive bladder cancer (NMIBC). Non-muscle-invasive bladder cancer is a heterogeneous disease that leads to significant variability in the intensity of surveillance and treatments to decrease the risk of local recurrences and progression to more invasive disease. National guidelines advocate for riskadapteddoi:10.1001/jamanetworkopen.2021.3816 pmid:33787916 fatcat:t5pkpff76nb5lcxfs3h4jk2u4m